Proactive Investors - Run By Investors For Investors

AIM Targeted Therapies seeks $16.5mln to further develop its two products

AIM Targeted Therapies CEO Dr. Glenn Abrahmsohn joins Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

The company is developing new solutions to address opioid addiction and antimicrobial resistance.

View full AIMTT profile View Profile

AIM Targeted Therapies Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use